The approval of subcutaneous amivantamab allows physicians flexibility in offering treatment for non–small cell lung cancer.
Equity Insider News Commentary – The U.S. oncology market is projected to surge from $81 billion in 2025 to $212 billion ...
The subcutaneous formulation of the bispecific antibody reduces treatment time to 1 minute vs 2-4 hours with IV infusion.
The FDA has granted approval to a subcutaneous formulation of mosunetuzumab (Lunsumio VELO; Genentech/Roche) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma ...
The U.S. Food and Drug Administration has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and ...
The US FDA has approved a subcutaneous version of Roche (RHHBY)-owned Genentech's follicular lymphoma treatment, Lunsumio ...
Three years after its initial FDA approval, Roche has made up for an early disadvantage with its blood cancer drug Lunsumio ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved CD20xCD3 bispecific Lunsumio VELO™ ...
Abstract: Background and Aim: Continuous subcutaneous insulin infusion (CSII) with sensor-augmented pumps is widely used in the treatment of type 1 diabetes. Patterning of glucose profiles using ...
Abstract: Intravenous (IV) therapy is a critical component of modern healthcare, yet traditional IV systems are prone to human errors, manual adjustments, and limited monitoring capabilities, which ...
ROCHESTER HILLS, Mich.--(BUSINESS WIRE)-- InfuSystem Holdings, Inc. (INFU) (“InfuSystem” or the “Company”), a leading national health care service provider, facilitating outpatient care for durable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback